Shots:

• The P-III CheckMate-214 study involves assessing of Opdivo (nivolumab- 3mg/kg) + Yervoy (ipilimumab-1mg/kg) vs sunitinib (50mg qd @4wks.) in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC)
• P-III Checkmate study results @30 months: OS (60% vs 47%); ORR (42% vs 29%); CR (11% vs 1%)- @ intention-to-treat (ITT): OS (64% vs 56%); ORR (41% vs 34%); CR (11% vs 2%)
• Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor targeted for cancer cells and is approved in 65 countries including the US- EU- Japan & China

Ref: BUSINESS WIRE | Image: Glassdoor